Blood pressure lowering treatment for preventing stroke recurrence: A systematic review and meta-analysis

International Archives of Medicine

Volumn 2, Issue 1, 2009, Pages

  Lakhan, Shaheen E ^a   Sapko, Michael T ^a  

^a Global Neuroscience Initiative Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; CANDESARTAN; DESERPIDINE; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; METHYCLOTHIAZIDE; NICARDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; UNCLASSIFIED DRUG;

ARTICLE; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; PATIENT IDENTIFICATION; RECURRENCE RISK; RECURRENT DISEASE; RISK REDUCTION; STROKE; STROKE PATIENT; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

EID: 77953468570     PISSN: None     EISSN: 17557682     Source Type: Journal    
DOI: 10.1186/1755-7682-2-30     Document Type: Article

References (38)

1. Blood pressure and risk of stroke in patients with cerebrovascular disease: the United Kingdom Transient Ischaemic Attack Collaborative Group. AMS Rodgers G Gamble J Slattery P Sandercock C Warlow, BMJ 1996 342 147
2. Age-related changes in risk factor effects on the incidence of thromboembolic and hemorrhagic stroke. RDCJ Abbott BL Rodriguez KH Masaki JS Popper GW Ross H Petrovitch, J Clin Epidemiol 2003 56 479 486 10.1016/S0895-4356(02)00611-X 12812823
3. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. RLAR Sacco G Albers MJ Alberts O Benavente K Furie LB Goldstein P Gorelick J Halperin R Harbaugh SC Johnston I Katzan M Kelly-Hayes EJ Kenton M Marks LH Schwamm T Tomsick American Heart Association; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology, Stroke 2006 37 677 617
4. Blood Pressure and Stroke: An Overview of Published Reviews. C Lawes DA Bennett VL Feigin A Rodgers, Stroke 2004 35 1024 1033 10.1161/01.STR.0000116869. 64771.5A 15053002
5. Blood pressure, stroke, and coronary heart disease, part I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. SPR MacMahon J Cutler R Collins P Sorlie J Neaton R Abbott J Godwin A Dyer J Stamler, Lancet 1990 335 765 774 10.1016/0140- 6736(90)90878-9 1969518
6. J curve in antihypertensive therapy: does it exist? A personal point of view. J Cruickshank, Cardiovasc Drugs Ther 1994 8 157 160 10.1007/BF00877123 (Pubitemid 24376756)
7. The J-curve phenomenon and the treatment of hypertension: is there a point beyond which pressure reduction is dangerous? LMC Farnett WD Linn CR Lucey MR Tuley, JAMA 1991 265 489 495 10.1001/jama.265.4.489 1824642
8. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000 342 145 153 10.1056/NEJM200001203420301 10639539
9. Use of ramipril in preventing stroke: double blind randomised trial. JYS Bosch J Pogue P Sleight E Lonn B Rangoonwala R Davies J Ostergren, BMJ 2002 324 699 702 10.1136/bmj.324.7339.699 11909785
10. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 358 1033 1041 10.1016/S0140-6736(01)06178-5 11589932
11. The lowering of blood-pressure after stroke. Lancet 2001 358 1994 1995 11747946
12. Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events: A Systematic Review. P Rashid J Leonardi-Be P Bath, Stroke 2003 34 2741 2748 10.1161/01.STR.0000092488.40085.15 14576382
13. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. N Engl J Med 2008 359 1225 1237 10.1056/NEJMoa0804593 18753639
14. The PROGRESS trial three years later: time for a balanced report of effectiveness. R Wennberg C Zimmermann, BMJ 2004 329 968 970 10.1136/bmj.329.7472.968 15499116
15. Review Manager (RevMan) Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration 2008
16. Quantifying heterogeneity in a meta-analysis. J Higgens SG Thompson, Statistics in Medicine 2002 21 1539 1558 10.1002/sim.1186 12111919
17. Bias in meta-analysis detected by a simple, graphical test. MDSG Egger M Schneider C Minder, BMJ 1997 315 629 634 9310563
18. Effect of antihypertensive treatment on stroke recurrence. JAMA 1974 229 409 418 10.1001/jama.229.4.409 4599980
19. Nicardipine in the prevention of cerebral infarction. J Martí Massá R Lozano, Clin Ther 1990 12 344 351 2224948
20. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 1993 24 543 548 8465360
21. Post-Stroke Antihypertensive Treatment Study: a preliminary result. Chin Med J 1995 108 710 717 8575241
22. Atenolol in secondary prevention after stroke. SOB-O Eriksson P-O Wester, Cerebrovasc Dis 1995 5 21 25 10.1159/000107813
23. Effects of blood pressure lowering treatment on stroke recurrence in patients with cerebrovascular diseases-a large-scale, randomized, placebo controlled trial. Zhonghua Xin Xue Guan Bing Za Zhi 2005 33 613 617 16080808
24. The Study on COgnition and Prognosis in the Elderly (SCOPE) - Major CV events and stroke in subgroups of patients. P Trenkwalder D Elmfeldt A Hofman H Lithell B Olofsson V Papademetriou I Skoog A Zanchetti, Blood Pressure 2005 14 31 37 10.1080/08037050510008823 15823945
25. The influence of nicardipine in patients with high risk of stroke. M Ribas Mundá R Lozano, J Cardiovasc Pharmacol 1990 16 16 19
26. Control of Hypertension and Risk of Stroke Recurrence. G Friday M Alter S-M Lai, Stroke 2002 33 2652 2657 10.1161/01.STR.0000033929.62136.6F 12411656
27. The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. J Schrader S Lüders A Kulschewski J Berger W Zidek J Treib K Einhäupl HC Diener P Dominiak Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group, Stroke 2003 34 1699 1703 10.1161/01.STR. 0000075777.18006.89 12817109
28. Angiotensin-Converting-Enzyme Inhibition in Stable Coronary Artery Disease. N Engl J Med 2004 351 2058 2068 10.1056/NEJMoa042739 15531767
29. Secondary prevention of stroke - results from the Southern Africa Stroke Prevention Initiative (SASPI) study. Bull World Health Organ 2004 82 2004 2008
30. Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES). Stroke 2005 34 1218 1224
31. Blood Pressure Level and Outcomes in Adults Aged 65 and Older with Prior Ischemic Stroke. R Kaplan DL Tirschwell WTJr Longstreth TA Manolio SR Heckbert AJ LeValley D Lefkowitz A El-Saed BM Psaty, J Am Geriatr Soc 2006 54 1309 1316 10.1111/j.1532-5415.2006.00838.x 16970636
32. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. AJS Zanchetti S Kjeldsen GT McInnes T Hua M Weber JH Laragh F Plat E Battegay C Calvo-Vargas A Cieliski JP Degaute NJ Holwerda J Kobalava OL Pedersen FP Rudyatmoko KC Siamopoulos O Störset, J Hypertens 2006 24 2163 2168 10.1097/01.hjh.0000249692.96488.46 17053536
33. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000 342 145 153 10.1056/NEJM200001203420301 10639539
34. Medications, Comorbidities, and Medical Complications in Stroke Survivors: The CAReS Study. S Ostwald J Wasserman S Davis, Rehabil Nurs 2006 31 10 14 16422039
35. Drug Therapy for the Secondary Prevention of Stroke in Hypertensive Patients. S Lüders, Drugs 2007 67 955 963 10.2165/00003495-200767070-00001 17488141
36. The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology 2004 62 2015 2020 15184607
37. Cause-specific mortality after first cerebral infarction: a population-based study. Stroke 2003 34 1828 1832 10.1161/01.STR.0000080534. 98416.A0 12855836
38. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. S Yusuf K Teo C Anderson J Pogue L Dyal I Copland H Schumacher G Dagenais P Sleight, Lancet 2008 372 1174 1183 10.1016/S0140-6736(08)61193-9 18757085